This week, we begin with a penny stock alert issued on a biopharmaceutical, development stage company we like (a lot) — Anavex Life Sciences Corp. (AVXL). The company has a lead drug candidate, ANAVEX 2-73, which scored much better Phase I results than many of the high-profile failures in the Alzheimer’s disease space. Considering that the upside potential for
Continue Reading →
5
NOV
0
Share